| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC1145 | Br-verapamil Hydrochloride | Novel Ca V channels blocker, binding in the central cavity of the pore on the intracellular side of the selectivity filter, physically blocking the ion-conducting pathway |
|
| DCC1146 | Bryostatin 2 | Protein kinase C (PKC) activator |
|
| DCC1147 | Bsc2118 | Novel proteasome inhibitor, protecting against cerebral ischaemia through HIF1A accumulation and enhanced angioneurogenesis |
|
| DCC1148 | bsc4090 | Fluorescent probe in vitro and in vivo aiming at a tau-based diagnosis of Alzheimer's disease |
|
| DCC1149 | bsc4704 | Fluorescent probe, binding to neurofibrillary tangles with high contrast and selectivity over amyloid |
|
| DCC1150 | Bsc4750 | Fluorescent probe visualizing neurofibrillary tangles in Alzheimer's disease |
|
| DCC1151 | Bsh-in-7 | Novel potent covalent inhibitor of gut bacterial bile salt hydrolases (BSH) |
|
| DCC1152 | Bss-730a | Novel potent inhibitor of both HIV-1 and HIV-2 replication, being also active against the erythrocytic stages of P. falciparum |
|
| DCC1153 | Bta9881 | Novel respiratory syncytial virus (RSV) fusion inhibitor |
|
| DCC1154 | btb02467 | Novel cell-permeable modulator of cellular morphogenesis in yeast and mammalian cells; Inhibitor of SARS-CoV Mpro activity via intensive H-bond network and hydrophobic interactions |
|
| DCC1155 | btb03156 | Novel cell-permeable modulator of cellular morphogenesis in yeast and mammalian cells |
|
| DCC1156 | btb03195 | Novel activator of PC1/3 and inhibitor of PC2 |
|
| DCC1157 | Btgh84 Activator I | Novel activator of BtGH84, the first experimentally discovered small molecule activator of a glycoside hydrolase |
|
| DCC1158 | Bti-a-404 | Novel selective and potent competitive inverse agonist of human GPR43 |
|
| DCC1159 | Btk-in-27 | Novel potent and selective covalent inhibitor of Bruton’s tyrosine kinase (BTK), targeting a noncatalytic cysteine residue (Cys481) for covalent bond formation |
|
| DCC1160 | Btk-in-3 | Novel potent inhibitor of Bruton’s tyrosine kinase (BTK) |
|
| DCC1161 | B-tpmf | The first small-molecule inhibitor with significant selectivity among the KCa2 channel subtypes |
|
| DCC1162 | Btt-3035 | Novel inhibitor of alpha2beta1 integrin, decreasing average platelet adhesion in individuals with the C/T807T genotype but not in those harboring C807C |
|
| DCC1163 | Btx-yne | Novel unique Na V modulator, acting as a conspicuous outlier, eliminating fast but not slow inactivation |
|
| DCC1164 | Btz-n3 | Novel effective reversible and noncovalent inhibitor of DprE1. |
|
| DCC1165 | Btzo-4 | Negative control for BTZO-1 |
|
| DCC1166 | Bu99008 | Ligand of the Imidazoline(2) binding site (I 2 BS), showing very good affinity for the I 2 BS (K i of 1.4 nM; K d = 1.3 nM), good selectivity compared with the α 2 -adrenoceptor (909-fold) |
|
| DCC1167 | Bucinnazine | Potent and selective agonist of μ-opioid receptor (MOR) with relatively low affinity for the δ-opioid receptor and the κ-opioid receptor |
|
| DCC1168 | Budralazine | Direct-acting vasodilator with anti-tachycardiac effect |
|
| DCC1169 | Bulgecin A Featured | Bulgecin A is an inhibitor of binuclear metallo-beta-lactamases and Lytic transglycosolase. |
|
| DCC1170 | Butafenacil | Potent inducer of anemia |
|
| DCC1171 | Butylcycloheptyl Prodiginine | Natural inhibitor of microRNA-21, reducing growth of cancer cells |
|
| DCC1172 | Bvt-116429 | Novel 11β-HSD1 inhibitor |
|
| DCC1173 | bvt-2733 Hydrochloride | Selective 11beta-hydroxysteroid dehydrogenase type 1 (11betaHSD1) inhibitor |
|
| DCC1174 | Bw2258u89 | Novel BB2 receptor antagonist. attenuating the feeding responses evoked by exogenous gastrin releasing peptide-29 |
|
